Scott Gottlieb, MD, was confirmed yesterday to head the FDA by a Senate vote of 57 to 42. Readers of Managed Care got some insight into Gottlieb’s priorities when we interviewed him last year.
The New York Times is reporting this morning that Gottlieb promises to “divest himself from several health care companies and recuse himself for one year from decisions involving those businesses….”
Some Democratic senators weren’t swayed. During the confirmation hearing, Sen. Patty Murray of Washington said, “He has not convinced me he can withstand political pressure from this administration, or that he will be truly committed to putting our families’ health first. I’ve grown increasingly concerned about whether he can lead the FDA in an unbiased way, given his unprecedented industry ties.”
Gottlieb, 44, is a resident fellow at the American Enterprise Institute and a leading conservative expert on health care policy. Gottlieb served on the advisory boards for GlaxoSmithKline and Daiichi Sankyo, as well as doing other consulting work for large drug companies.
The New York Times: “Supporters of Dr. Gottlieb’s nomination have said his business experience will serve him well as head of the FDA, and friends and associates have described him as an independent thinker who will not always side with industry.”
As we reported earlier this year, here are some other things you might want to know about Gottlieb:
Source: New York Times